Spyre Therapeutics, Inc. (SYRE): who owns it and who trades it
As of Nov 16, 2026, SYRE insiders reported 94 open-market sales worth $442M and no purchases in the last 12 months, with 9% of the sale value made under pre-set 10b5-1 plans. The largest seller was Fairmount Funds Management LLC (Director), with $400M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Spyre Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SYRE
263 funds and institutions reported SYRE shares worth $8.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 13.03M | 15.00% | $1.2B | +11% |
| BlackRock, Inc. | 6.51M | 7.49% | $578M | +18% |
| Perceptive Advisors LLC | 4.32M | 4.97% | $383M | +14% |
| Rtw Investments, LP | 4.25M | 4.90% | $377M | +2% |
| Paradigm Biocapital Advisors LP | 3.84M | 4.42% | $341M | +96% |
| Vanguard Capital Management LLC | 3.45M | 3.97% | $306M | +13% |
| State Street Corp | 3.06M | 3.52% | $271M | +17% |
| Venrock Adviser, LLC | 2.99M | 3.44% | $265M | -19% |
| T. Rowe Price Associates | 2.96M | 3.41% | $263M | +85% |
| Driehaus Capital Management LLC | 2.80M | 3.22% | $249M | +0% |
| Geode Capital Management, LLC | 2.56M | 2.95% | $239M | +49% |
| Vanguard Portfolio Management LLC | 2.33M | 2.68% | $207M | +298% |
| Capital World Investors | 2.32M | 2.67% | $206M | +247% |
| Jupiter Topco LLC | 2.21M | 2.54% | $196M | – |
| TCG Crossover Management, LLC | 1.90M | 2.19% | $169M | No change |
| Tang Capital Management LLC | 1.89M | 2.18% | $168M | No change |
| Bank of America Corp | 1.78M | 2.05% | $158M | +45% |
| Adage Capital Partners Gp, L.l.c. | 1.72M | 1.98% | $153M | – |
| Wellington Management Group LLP | 1.58M | 1.82% | $140M | -13% |
| Goldman Sachs Group Inc | 1.48M | 1.70% | $131M | +448% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SYRE insiders reported $0 of open-market purchases and $442M of sales. 9% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Scott L Burrows | CFO | Sale plan | 600 | $89.07 | $53.4K | Form 4 |
| Oct 1, 2026 | Scott L Burrows | CFO | Sale plan | 1,500 | $90.27 | $135K | Form 4 |
| Oct 1, 2026 | Scott L Burrows | CFO | Sale plan | 2,100 | $91.92 | $193K | Form 4 |
| Oct 1, 2026 | Scott L Burrows | CFO | Sale plan | 3,071 | $92.95 | $285K | Form 4 |
| Oct 1, 2026 | Scott L Burrows | CFO | Sale plan | 229 | $93.57 | $21.4K | Form 4 |
| Oct 1, 2026 | Heidy King-Jones | See Remarks | Sale plan | 400 | $89.24 | $35.7K | Form 4 |
| Oct 1, 2026 | Heidy King-Jones | See Remarks | Sale plan | 16,605 | $90.35 | $1.5M | Form 4 |
| Oct 1, 2026 | Heidy King-Jones | See Remarks | Sale plan | 7,228 | $91.35 | $660K | Form 4 |
| Oct 1, 2026 | Heidy King-Jones | See Remarks | Sale plan | 2,100 | $92.70 | $195K | Form 4 |
| Oct 1, 2026 | Heidy King-Jones | See Remarks | Sale plan | 2,600 | $93.46 | $243K | Form 4 |
| Oct 1, 2026 | Cameron Turtle | CEO | Sale plan | 600 | $89.14 | $53.5K | Form 4 |
| Oct 1, 2026 | Cameron Turtle | CEO | Sale plan | 2,683 | $90.10 | $242K | Form 4 |
| Oct 1, 2026 | Cameron Turtle | CEO | Sale plan | 2,638 | $91.49 | $241K | Form 4 |
| Oct 1, 2026 | Cameron Turtle | CEO | Sale plan | 3,989 | $92.31 | $368K | Form 4 |
| Oct 1, 2026 | Cameron Turtle | CEO | Sale plan | 4,990 | $93.37 | $466K | Form 4 |
| Oct 1, 2026 | Cameron Turtle | CEO | Sale plan | 100 | $93.91 | $9.4K | Form 4 |
| Sep 30, 2026 | Scott L Burrows | CFO | Sale plan | 17,500 | $89.89 | $1.6M | Form 4 |
| Sep 2, 2026 | Heidy King-Jones | See Remarks | Sale plan | 400 | $90.00 | $36K | Form 4 |
| Sep 2, 2026 | Scott L Burrows | CFO | Sale plan | 18,232 | $89.35 | $1.6M | Form 4 |
| Sep 1, 2026 | Heidy King-Jones | See Remarks | Sale plan | 4,845 | $86.40 | $419K | Form 4 |
| Sep 1, 2026 | Heidy King-Jones | See Remarks | Sale plan | 16,548 | $87.20 | $1.4M | Form 4 |
| Sep 1, 2026 | Heidy King-Jones | See Remarks | Sale plan | 6,206 | $88.17 | $547K | Form 4 |
| Sep 1, 2026 | Heidy King-Jones | See Remarks | Sale plan | 400 | $89.38 | $35.8K | Form 4 |
| Sep 1, 2026 | Scott L Burrows | CFO | Sale plan | 200 | $89.04 | $17.8K | Form 4 |
| Sep 1, 2026 | Scott L Burrows | CFO | Sale plan | 2,016 | $88.03 | $177K | Form 4 |
| Sep 1, 2026 | Scott L Burrows | CFO | Sale plan | 900 | $86.25 | $77.6K | Form 4 |
| Sep 1, 2026 | Scott L Burrows | CFO | Sale plan | 4,384 | $87.11 | $382K | Form 4 |
| Sep 1, 2026 | Cameron Turtle | CEO | Sale plan | 8,400 | $87.15 | $732K | Form 4 |
| Sep 1, 2026 | Cameron Turtle | CEO | Sale plan | 2,500 | $86.36 | $216K | Form 4 |
| Sep 1, 2026 | Cameron Turtle | CEO | Sale plan | 400 | $89.07 | $35.6K | Form 4 |
| Sep 1, 2026 | Cameron Turtle | CEO | Sale plan | 3,700 | $88.06 | $326K | Form 4 |
| Aug 7, 2026 | Jeffrey W. Albers | Director | Sale plan | 5,000 | $104.47 | $522K | Form 4 |
| Aug 7, 2026 | Jeffrey W. Albers | Director | Sale plan | 8,000 | $104.38 | $835K | Form 4 |
| Aug 7, 2026 | Jeffrey W. Albers | Director | Sale plan | 10,000 | $104.68 | $1M | Form 4 |
| Aug 3, 2026 | Scott L Burrows | CFO | Sale plan | 2,300 | $96.30 | $221K | Form 4 |
| Aug 3, 2026 | Scott L Burrows | CFO | Sale plan | 5,100 | $95.21 | $486K | Form 4 |
| Aug 3, 2026 | Scott L Burrows | CFO | Sale plan | 100 | $97.10 | $9.7K | Form 4 |
| Aug 3, 2026 | Cameron Turtle | CEO | Sale plan | 800 | $93.97 | $75.2K | Form 4 |
| Aug 3, 2026 | Cameron Turtle | CEO | Sale plan | 7,157 | $95.10 | $681K | Form 4 |
| Aug 3, 2026 | Cameron Turtle | CEO | Sale plan | 5,635 | $95.93 | $541K | Form 4 |
| Aug 3, 2026 | Cameron Turtle | CEO | Sale plan | 1,392 | $96.82 | $135K | Form 4 |
| Aug 3, 2026 | Cameron Turtle | CEO | Sale plan | 16 | $97.46 | $1.6K | Form 4 |
| Jul 1, 2026 | Scott L Burrows | CFO | Sale plan | 5,775 | $87.55 | $506K | Form 4 |
| Jul 1, 2026 | Scott L Burrows | CFO | Sale plan | 1,725 | $88.37 | $152K | Form 4 |
| Jul 1, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 1,834 | $88.34 | $162K | Form 4 |
| Jul 1, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 6,500 | $87.52 | $569K | Form 4 |
| Jul 1, 2026 | Cameron Turtle | CEO | Sale plan | 4,234 | $88.12 | $373K | Form 4 |
| Jul 1, 2026 | Cameron Turtle | CEO | Sale plan | 590 | $88.91 | $52.5K | Form 4 |
| Jul 1, 2026 | Cameron Turtle | CEO | Sale plan | 10,176 | $87.44 | $890K | Form 4 |
| Jun 25, 2026 | Scott L Burrows | CFO | Sale | 5,000 | $87.12 | $436K | Form 4 |
| Jun 25, 2026 | Scott L Burrows | CFO | Sale | 10,000 | $87.14 | $871K | Form 4 |
| Jun 23, 2026 | Fairmount Funds Management LLC +3 | Director | Sale | 4.68M | $85.31 | $400M | Form 4 |
| Jun 22, 2026 | Michael Thomas Henderson | Director | Sale plan | 20,000 | $100.00 | $2M | Form 4 |
| Jun 3, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 8,333 | $75.00 | $625K | Form 4 |
| Jun 1, 2026 | Cameron Turtle | CEO | Sale plan | 3,294 | $71.38 | $235K | Form 4 |
| Jun 1, 2026 | Cameron Turtle | CEO | Sale plan | 8,149 | $70.50 | $575K | Form 4 |
| Jun 1, 2026 | Cameron Turtle | CEO | Sale plan | 3,557 | $69.40 | $247K | Form 4 |
| Jun 1, 2026 | Scott L Burrows | CFO | Sale plan | 3,100 | $72.06 | $223K | Form 4 |
| Jun 1, 2026 | Scott L Burrows | CFO | Sale plan | 2,599 | $70.77 | $184K | Form 4 |
| Jun 1, 2026 | Scott L Burrows | CFO | Sale plan | 1,801 | $69.75 | $126K | Form 4 |
| May 8, 2026 | Michael Thomas Henderson | Director | Sale plan | 2,404 | $72.57 | $174K | Form 4 |
| May 8, 2026 | Michael Thomas Henderson | Director | Sale plan | 24,814 | $74.76 | $1.9M | Form 4 |
| May 8, 2026 | Michael Thomas Henderson | Director | Sale plan | 19,269 | $75.35 | $1.5M | Form 4 |
| May 8, 2026 | Michael Thomas Henderson | Director | Sale plan | 33,513 | $73.72 | $2.5M | Form 4 |
| May 1, 2026 | Scott L Burrows | CFO | Sale plan | 12,500 | $71.37 | $892K | Form 4 |
| May 1, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 5,059 | $74.60 | $377K | Form 4 |
| May 1, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 10,358 | $73.74 | $764K | Form 4 |
| May 1, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 12,777 | $72.94 | $932K | Form 4 |
| May 1, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 8,777 | $71.56 | $628K | Form 4 |
| May 1, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 19,656 | $70.61 | $1.4M | Form 4 |
| May 1, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 400 | $75.37 | $30.1K | Form 4 |
| May 1, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 21,306 | $69.53 | $1.5M | Form 4 |
| May 1, 2026 | Cameron Turtle | CEO | Sale plan | 3,100 | $73.14 | $227K | Form 4 |
| May 1, 2026 | Cameron Turtle | CEO | Sale plan | 1,000 | $71.76 | $71.8K | Form 4 |
| May 1, 2026 | Cameron Turtle | CEO | Sale plan | 3,600 | $70.77 | $255K | Form 4 |
| May 1, 2026 | Cameron Turtle | CEO | Sale plan | 5,300 | $69.54 | $369K | Form 4 |
| May 1, 2026 | Cameron Turtle | CEO | Sale plan | 300 | $74.96 | $22.5K | Form 4 |
| May 1, 2026 | Cameron Turtle | CEO | Sale plan | 1,700 | $74.23 | $126K | Form 4 |
| Apr 1, 2026 | Cameron Turtle | CEO | Sale plan | 2,656 | $49.92 | $133K | Form 4 |
| Apr 1, 2026 | Cameron Turtle | CEO | Sale plan | 12,344 | $49.20 | $607K | Form 4 |
| Apr 1, 2026 | Sheldon Sloan | Chief Medical Officer | Sale plan | 7,958 | $50.00 | $398K | Form 4 |
| Apr 1, 2026 | Scott L Burrows | CFO | Sale plan | 6,200 | $49.21 | $305K | Form 4 |
| Apr 1, 2026 | Scott L Burrows | CFO | Sale plan | 1,300 | $49.98 | $65K | Form 4 |
| Mar 3, 2026 | Scott L Burrows | CFO | Sale plan | 200 | $41.66 | $8.3K | Form 4 |
| Mar 3, 2026 | Scott L Burrows | CFO | Sale plan | 2,300 | $40.56 | $93.3K | Form 4 |
| Mar 2, 2026 | Cameron Turtle | CEO | Sale plan | 9,100 | $42.49 | $387K | Form 4 |
| Mar 2, 2026 | Cameron Turtle | CEO | Sale plan | 5,900 | $41.73 | $246K | Form 4 |
| Feb 2, 2026 | Cameron Turtle | CEO | Sale plan | 957 | $31.82 | $30.5K | Form 4 |
| Feb 2, 2026 | Cameron Turtle | CEO | Sale plan | 14,043 | $32.87 | $462K | Form 4 |
| Jan 2, 2026 | Cameron Turtle | CEO | Sale plan | 12,709 | $30.47 | $387K | Form 4 |
| Jan 2, 2026 | Cameron Turtle | CEO | Sale plan | 100 | $32.39 | $3.2K | Form 4 |
| Jan 2, 2026 | Cameron Turtle | CEO | Sale plan | 2,191 | $31.79 | $69.7K | Form 4 |
| Dec 1, 2025 | Cameron Turtle | CEO | Sale plan | 4,005 | $29.83 | $119K | Form 4 |
| Dec 1, 2025 | Cameron Turtle | CEO | Sale plan | 10,995 | $28.73 | $316K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Fairmount Funds Management LLC | Director | – | $400M | Jun 23, 2026 |
| Cameron Turtle | Chief Executive Officer, Director | – | $10.3M | Oct 1, 2026 |
| Scott L Burrows | Chief Financial Officer | – | $9.1M | Oct 1, 2026 |
| Michael Thomas Henderson | Director | – | $8M | Jun 22, 2026 |
| Sheldon Sloan | Chief Medical Officer | – | $7.4M | Jul 1, 2026 |
| Heidy King-Jones | See Remarks | – | $5.1M | Oct 1, 2026 |
| Jeffrey W. Albers | Director | – | $2.4M | Aug 7, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SYRE short interest
High short interest. 12.2% of SYRE shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 6%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 11.62M SYRE shares were sold short, 12.2% of the shares outstanding, down 7.1% from the report before. At the average daily volume of 915,434 shares, buying them all back would take about 12.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.62M | 12.23% | -7% | 915,434 | 12.7 |
| Oct 15, 2026 | 12.51M | 14.18% | -3% | 1.70M | 7.3 |
| Sep 30, 2026 | 12.84M | 14.57% | +6% | 1.44M | 8.9 |
| Sep 15, 2026 | 12.13M | 13.76% | +2% | 1.05M | 11.6 |
| Aug 31, 2026 | 11.86M | 13.45% | +1% | 1.22M | 9.7 |
| Aug 14, 2026 | 11.76M | 13.33% | -3% | 736,817 | 15.9 |
| Jul 31, 2026 | 12.14M | 13.77% | -3% | 898,547 | 13.5 |
| Jul 15, 2026 | 12.51M | 14.40% | -8% | 1.39M | 9.0 |
| Jun 30, 2026 | 13.64M | 15.71% | +8% | 2.46M | 5.6 |
| Jun 15, 2026 | 12.62M | 14.53% | -0% | 1.17M | 10.8 |
| May 29, 2026 | 12.63M | 14.54% | +2% | 816,178 | 15.5 |
| May 15, 2026 | 12.42M | 14.30% | +2% | 1.19M | 10.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Spyre Therapeutics company events
Spyre Therapeutics filed 14 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Oct 7, 2026AgreementSpyre Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as the representatives of the underwriters named therein, relating to the offer and sale of 4,117,648 shares of the… Filing
- Sep 8, 2026AnnouncementThe Company announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investigated for the treatment of moderately-to-severely active UC. SPY003 SKYLINE Part A Induction Topline Results Efficacy: POC Established Across All Three… Filing
- Aug 25, 2026AnnouncementThe Company announced topline results from the RA sub-study of the Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jun 15, 2026AnnouncementThe Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 for the treatment of moderately-to-severely active UC. SPY002 SKYLINE Part A Induction Topline Results Initial 12-week findings from SKYLINE Part A demonstrated that SPY002 met… Filing
- Jun 1, 2026AnnouncementThe Company entered into the First Amendment to Amended and Restated License Agreement, amending the Amended and Restated License Agreement dated as of February 24, 2025 (as amended, the "SPY003 License Agreement"), by and between the Company and Paragon Therapeutics, Inc. Filing
- May 29, 2026LeadershipAs discussed in Item 5.07 below, upon the recommendation of the Board of Directors of Spyre Therapeutics, Inc., the stockholders of the Company, at the Company’s Annual Meeting of Stockholders held on May 27, 2026, approved the amended and restated 2016 Employee Stock Purchase Plan. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 16, 2026AgreementSpyre Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters named therein, relating to the offer and sale of 6,500,000 shares of the Company’s common… Filing
- Apr 13, 2026AnnouncementThe Company suspended and terminated the prospectus relating to the sale of its common stock, $0.0001 par value per share in an “at-the-market” offering pursuant to the terms of the Sales Agreement, dated, September 6, 2024, by and between the Company and TD Securities (USA) LLC. Filing
- Apr 13, 2026AnnouncementThe Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for the treatment of moderate-to-severely active UC. Additionally, the Company announced that recruitment for Part A of the SKYLINE Trial is now closed and enrollment is open for… Filing
- Feb 19, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Spyre Therapeutics financials
Famous investors that hold SYRE
3 of the 50 well-known investors we track reported holding SYRE in their latest 13F filing. The largest position is Steve Cohen's, worth $31.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 356,923 | $31.8M | 0.1% | New |
| Israel Englander · Millennium Management | Q3 2026 | 241,548 | $21.5M | 0.0% | +23% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 20,097 | $1.8M | 0.0% | -81% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named SYRE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 9, 2026 | Fairmount Funds Management LLC | 13D/A | 9.2% |
| Oct 9, 2026 | Fairmount Funds Management LLC | 13D/A | 9.2% |
| Oct 1, 2026 | Paradigm BioCapital Advisors LP | 13G | 5.1% |
| Oct 1, 2026 | Paradigm BioCapital Advisors LP | 13G | 5.1% |
Questions about Spyre Therapeutics, Inc. (SYRE) stock
Who owns the most SYRE stock?
The largest reported owner of Spyre Therapeutics, Inc. (SYRE) is FMR LLC (Fidelity), with 15.0% of the company. In total, 263 funds and institutions reported holding SYRE at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are SYRE insiders buying or selling?
In the last 12 months, SYRE insiders reported no open-market purchases and 94 sales worth $442M. The latest trade was on Oct 1, 2026. See every trade.
What is the short interest in SYRE?
As of Oct 30, 2026, 11.62M SYRE shares were sold short, 12.2% of the shares outstanding, down 7.1% from the report before. At the average daily volume of 915,434 shares, buying them all back would take about 12.7 trading days (days to cover). See the history.
Which famous investors hold SYRE?
3 of the 50 well-known investors we track reported SYRE in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $31.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.